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Acquisition of natural humoral 
immunity to P. falciparum in early 
life in Benin: impact of clinical, 
environmental and host factors
Célia Dechavanne1,2,†, Ibrahim Sadissou3, Aziz Bouraima3, Claude Ahouangninou3, 
Roukiyath Amoussa3, Jacqueline Milet1,2, Kabirou Moutairou4, Achille Massougbodji4, 
Michael Theisen5,6, Edmond J. Remarque7, David Courtin1,2, Gregory Nuel8, Florence  
Migot-Nabias1,2 & André Garcia1,2
To our knowledge, effects of age, placental malaria infection, infections during follow-up, nutritional 
habits, sickle-cell trait and individual exposure to Anopheles bites were never explored together in a 
study focusing on the acquisition of malaria antibody responses among infants living in endemic areas.
Five hundred and sixty-seven Beninese infants were weekly followed-up from birth to 18 months of age. 
Immunoglobulin G (IgG), IgG1 and IgG3 specific for 5 malaria antigens were measured every 3 months. 
A linear mixed model was used to analyze the effect of each variable on the acquisition of antimalarial 
antibodies in 6-to18-month old infants in univariate and multivariate analyses. Placental malaria, 
nutrition intakes and sickle-cell trait did not influence the infant antibody levels to P. falciparum 
antigens. In contrary, age, malaria antibody levels at birth, previous and present malaria infections as 
well as exposure to Anopheles bites were significantly associated with the natural acquisition of malaria 
antibodies in 6-to18-month old Beninese infants. This study highlighted inescapable factors to consider 
simultaneously in an immuno-epidemiological study or a vaccine trial in early life.
Naturally-acquired immunity to malaria develops slowly following repeated exposures to Plasmodium falci-
parum. Parasite, host, environmental and behavioral factors are essential to be examined for a better understand-
ing of the acquisition of clinical immunity and thus clinical outcomes of malaria infections. To our knowledge, 
this was not exhaustively investigated in previous studies. Indeed, Dobaño et al. evaluated the age dependence of 
naturally acquired antibodies to Merozoite Surface Protein (MSP) 1-19, Apical Membrane Antigen 1 (AMA1), 
and Erythrocyte Binding Antigen 175 only on the basis of past and present parasite exposure, occurrence of 
previous episodes and neighborhood of residence1. Moreover, Sarr et al. showed that malaria specific antibody 
responses increased with age in children under 5 years old2. Baird et al. clearly showed that host age, independent 
of cumulative exposure, represents a determinant key of the quantitative and qualitative immunoglobulin G (IgG) 
response to P. falciparum, certainly through an immune system maturation process3. In fact, the role of age in 
this process is complex and cannot be only related to protection increasing with age as a cumulative product of 
exposure to antigen4.
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Environmental factors also influence malaria specific antibody levels. Sarr et al., concluded that malaria anti-
body responses differed according to the areas where distinct Anopheles species evolve2. Drakeley et al. have 
observed significant associations between parasite prevalence, altitude, as well as recent rainfalls and the preva-
lence of antibodies specific for MSP1-19 in individuals between 3 to 45 years old5. Khaireh et al. showed a lower 
risk to be seropositive to P. falciparum for people living at more than 1.5 km of lakes and rivers6. Brought together, 
these examples illustrate the necessity to circumscribe the local environmental characteristics that may influence 
the acquisition of antimalarial antibodies.
Other factors may be incriminated such as malnutrition. Indeed, low levels of IgG directed to SPf66 and the 
Ring-infected Erythrocyte Surface Antigen have been shown in wasted children7,8.
The genotype AS of hemoglobin (Hb) is the main host genetic factor that confers a resistance to severe 
malaria9. Williams et al. showed that the HbAS protection occurred during the first 10 years of life. The authors 
proposed that this innate protection would allow the host to be exposed safely to malaria antigens capable of 
inducing malaria specific immunity10.
Finally, placental malaria could influence the development of immunity in newborns since studies suggested 
that offspring of women with placental malaria are more susceptible to malaria during infancy11,12. Moreover, 
Bonner et al. showed that the development of malaria specific antibody responses was impaired during the first 
year of an infant born to a mother with placental malaria at delivery13. Dent et al., showed that infants born to 
mothers with pregnancy-associated malaria without MSP1-driven cord blood lymphocyte responses had a lower 
functional activity of anti-MSP1 antibodies from 18 to 30 months in comparison to the other infants14. However, 
these results are inconsistent in the literature. Malhotra et al, did not found any difference in anti-MSP1 and 
anti-AMA1 IgG levels between infants born to mothers with or without placental malaria11.
The present work is based on an epidemiological study already described12 in which all these concurrent 
determinants were collected in order to be explored as a whole in relation to malaria immunity. It focused on the 
IgG, IgG1 and IgG3 – that seem to be main actors in malaria antibody responses15 – specific for 5 malaria anti-
gens selected i) for their abundance on the merozoite surface and thus their accessibility to host antibodies, and 
ii) because they are promising vaccine candidates that could induce protective immune responses16,17. The aims 
were i) to explore the development of IgG, IgG1 and IgG3 responses to P. falciparum blood-stage antigens from 
birth to 18 months and ii) to understand what are the key factors that could influence the emergence of antibody 
responses in infants.
Results
Descriptive results. The results presented in the Figs 1, 2 and 3 showed the raw data of IgG, IgG1 and IgG3 
acquired in concentration (μ g/mL) without statistical test associated.
From birth to 6 months of age, maternal IgG, IgG1 and IgG3 are decreasing in infant blood and after 6 months 
of age the infant antibodies are produced. This production is increasing with age as we can visualize that at 6 
months the level of specific IgG, IgG1 or IgG3 and total IgG are lower than at 18 months of age. For AMA1, 
the concentration of specific IgG/IgG1/IgG3 is stronger than for all the other antigens. The same effect is still 
observed but instead to see a decrease/increase at 6 months of age, the phenomenon is observed at 12 months of 
age (raw data in Fig. 1). For all antigens, including MSP2 from the age of 6 months, IgG1 represented the major 
part of the IgG response. Concerning MSP2 isoforms, IgG3 levels in mother, cord and 3-month blood were i) 
higher or equal to IgG1 levels and ii) higher than IgG3 levels directed to the other antigens.
Infants with no detected malaria infection during the follow-up were selected in the Fig. 2A. Antibody levels 
are never null (consistent with undetected infections) but still lower than in infants with at least one infection. 
In graphs B to E, infants infected only once during the follow-up were selected. Antibody responses following a 
malaria infection were represented by a positive slope. Antibody levels increased with age and this effect was more 
marked for infections occurring after 1 year of age.
Figure 3 illustrates the boosting effect on the IgG, IgG1 and IgG3 levels of two consecutive infections during 
a 6-month observation window. For most antigens, the second infection seems associated with an increasing 
specific IgG response whereas this trend is less clear for IgG1 and IgG3. The multivariate analysis will examine 
these results in more depth.
Univariate analyses. The nutritional status was not associated with antibody levels (P > 0.20). Although 
the sickle-cell trait was negatively associated with the acquisition of IgG3 to MSP2-FC27, this effect was not 
significant (P = 0.26). IgG levels to P. falciparum in infants aged more than 6 months were positively associated 
with maternal (all P < 0.001 except IgG3 to MSP2-FC27 (P = 0.021) and to MSP3 (P = 0.004)), cord (all P < 0.001 
except IgG3 to GLURP-R2 (P = 0.017)) and 3-month-infant (all P < 0.001) antibody levels with the strongest 
effect observed in cord blood. Placental malaria infection was not associated with specific IgG levels.
Multivariate final model. Table 1 shows the final model for each antibody response in infants aged more 
than six months. Overall, age, malaria specific antibody levels in cord blood and at 3 months, an infection having 
occurred either at the 3-month period or at the 3-to-6-month period before antibody measurement and envi-
ronmental factors were significantly associated with the acquisition of antigen-specific IgG (data not shown), 
IgG1 and IgG3 in 6-to-18-month old infants. Age has a polynomial effect and, after a decrease from 6 to 9 or 12 
months (depending on antibody), all the levels increased regularly until the age of 18 months (data not shown) 
as illustrated by the raw data in Fig. 1. Infections at 3–6 months of age were not significant, probably due to the 
immaturity of the newborn immune system and to the amount of maternal antibodies that could hide the slow 
acquisition. Contrarily, infections occurring either at the 3-month period or at the 3-to-6-month period before 
antibody measurement were positively significantly associated with the levels of antibodies. However, the effects 
of age and of infection on the evolution of antibody levels are complex, and a strong interaction (p < 10−3 for 
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each antibody response) was detected between age and infections. This result is consistent with the fact that an 
infection occurring later in the follow-up had a stronger effect on the antibody response than an infection occur-
ring early after birth when the immune system can be considered as less mature (Fig. 4). This effect of age has 
been already shown by Baird et al., who hypothesized that heavy exposure to infection among children, whether 
recent or lifelong, does not induce adult-like protection due to the maturation of adult immune system compared 
with infants3. However, we also showed that infection having occurred at the 3-to-6-month period before anti-
body measurement significantly increased the antibody response showing that the repetitions of infections and, 
indirectly the delay from the last infection, is an important factor in the acquisition of immunity. The environ-
mental variable was very often significantly associated with high antibody levels (Table 1). Placental malaria and 
sickle-cell trait were not significant in the multivariate analyses.
Discussion
The purposes of this work were i) to explore the acquisition of IgG, IgG1 and IgG3 responses to P. falciparum 
blood-stage antigens from birth to 18 months and ii) to highlight the factors that could influence the acquisition 
of these antibody responses in infant.
Infants with no detected malaria infection presented low but nonzero P. falciparum antibody responses allow-
ing 2 complementary interpretations: i) even with a close survey, an infant can develop unperceived infections 
and ii) malaria specific immune response would subtly develop in infant following submicroscopic infections. The 
strong effect of the environmental variable corroborates both explanations: P. falciparum exposure was related to 
the specific antibody response in 6–18 months old infants. This variable was inseparable from the presence of 
anopheles18 and furthermore was found strongly associated with the occurrence of the first malaria infection in 
the same cohort19. Pombo et al. showed that protection could be induced by sub-clinical infections with very low 
circulating parasites20 allowing to conclude that residing in a malaria endemic area is sufficient to induce a subtle 
development of anti-plasmodial immune responses. The present results underline the importance to take into 
account as precisely as possible the exposure to P. falciparum during sero-epidemiological studies.
An infection occurring in the 3-to-6-month period before the antibody measurement could be followed or 
not by an infection in the 3-month period. In case of no infection occurring during the 3-month period before 
Figure 1. Total IgG and IgG, IgG1 and IgG3 concentrations specific to blood stage antigens in mothers and 
infants up to 18 months of age Antibody levels determined in: Ci: peripheral maternal blood; CO: cord 
blood; 3, 6, 9, 12, 15 and 18 months of infants’ age. The full line in the box represents median values. Also 
shown are 10, 25, 75 and 90% percentiles of the IgG, IgG1 and IgG3 concentrations specific for each malaria 
antigen. For each time point, the group size is: Ci: n = 525, CO: n = 525, 3: n = 374, 6: n = 384, 9: n = 409, 12: 
n = 418, 15: n = 431, 18: n = 442.
www.nature.com/scientificreports/
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the antibody measurement, there was a positive “residual effect” on the level of total and cytophilic IgG, of the 
infection having occurred in the last 3-to-6 month period. In case of an additional infection during the 3-month 
period before the antibody measurement, the malaria specific antibody levels were boosted (2 consecutive infec-
tions). This is consistent with the development of an immune memory for infants living in an endemic area. 
Additionally, the quantification of memory B cells (CD19+ CD21+ CD27+ ) would represent a substantial infor-
mation especially as Ngundu et al., did not show any correlation between malaria antibody levels and memory B 
cell frequencies21.
In the present study, the 6–18 months infants’ levels of antimalarial antibodies were not related to placental 
malaria. These results are consistent with those of Malhotra et al. who followed-up a birth cohort in Kenya and 
found no age-linked differences in anti-malaria IgG levels between not exposed, exposed-and-not-sensitized and 
sensitized groups of children11. Contrarily, Bonner et al. showed that antimalarial antibody responses decreased 
during the first year of an infant born to a mother with placental malaria at delivery13. However, these authors 
compared time-pooled measures (0–4 months and 4–12 months) that could amplify the differences between 
infants born to mothers with and without placental malaria at delivery. In the birth cohort under study, infants 
born to mothers with placental malaria developed a malaria infection earlier compared to others12. According 
to the present results, the evolution of the infants’ malaria antibody responses seems not to be involved in this 
phenomenon. Indeed, Malhotra et al. also observed that tolerant (exposed-and-not-sensitized) children had 
impaired functional antibody responses to MSP1-1914. An investigation of the impact of antimalarial antibodies 
on protection to clinical malaria would lead to conclude on the role of these antibodies in infants born to mothers 
with placental malaria.
Figure 2. Acquisition of IgG to malaria blood stage antigens for infant with one malaria infection during the 
follow-up: effect of age (A): infants with no malaria infection. Each B-to-E panel concerns distinct children 
selected on the basis of their first (and only one) malaria infection that occurred either between (B) 6–9 months 
of age or (C) 9–12 months of age or (D) 12–15 months of age or (E) 15–18 months of age; n: number of infants 
in each group.
www.nature.com/scientificreports/
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Cord blood malaria antibody levels were positively associated with P. falciparum IgG, IgG1 and IgG3 levels 
during the follow-up were not associated with placental malaria. This result means that the infants born with 
high levels of transplacental transferred maternal antibodies to malaria produced high levels of IgG specific for 
malaria. If we consider the hypothesis according to which antibodies are markers of exposure, the higher malaria 
infections would occur in infants the higher the malaria antibody levels would be. It was previously demonstrated 
in this cohort that infants born to mothers with placental malaria had a higher risk of malaria infection in their 18 
first months of age19. Antibodies as markers of exposure could thus potentially explain this result. The literature 
provides contradictory conclusions regarding maternal antimalarial antibodies transferred to the fetus and pro-
tection of infant from early malaria infections22. Regarding the present study, the number of malaria infections 
up to the age of 6 months was not associated with the transfer of malaria-specific IgG from the mother to the 
fetus, leading to the conclusion that malaria-specific IgG represented a marker of maternal exposure rather than 
a marker of infant protection from malaria23.
Nutritional intakes had no effect on malaria specific antibody levels. Genton et al. found no association 
between antibody levels to MSP1 and MSP2 and nutritional status7. However, in the present study nutritional 
intakes were assessed by means of 24-Hour Dietary Recall questionnaire and not by nutrients measurements 
whereas nutrients are constitutional components of the immune response24. Among them, zinc deficiency has 
been shown to compromise the B lymphocyte development and therefore the antibody production25. Further 
investigations on the nutritional status at the nutrient level and its impact on the acquisition of malaria specific 
immunity are necessary.
Figure 3. Effect of two successive 3-month periods with malaria infections on the acquisition of IgG, IgG1 and 
IgG3 to malaria blood stage antigens The panel (A) represents the mean concentration of IgG, IgG1 and IgG3 
specific for malaria antigens in the 7 infants with a first malaria infection between 9–12 months and a second 
infection between 12–15 months. The panel (B) represents the mean concentration of IgG, IgG1 and IgG3 
specific for malaria antigens in the 21 infants with a first malaria infection between 12–15 months and a second 
infection between 15–18 months; n: number of infants in each group.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:33961 | DOI: 10.1038/srep33961
Sickle-cell trait was not significantly associated with antibody evolution in the univariate or multivariate 
analyses.
In the present work, antibody responses were analyzed independently. The profiles of malaria antibody con-
centrations in infant are similar over the time as those expressed in arbitrary units or in OD values in other stud-
ies26–28. Antibody response curves vary depending on merozoite antigens and IgG subclasses - as illustrated by 
the higher level of IgG3 specific for MSP2 in women (as described elsewhere29) - and they result from the sum of 
individual responses, each being characterized by defined subpopulations of IgG antibody-secreting cells28. The 
next step will consist to take into account the synergy of the antibody responses directed to the five studied anti-
gens, in order to obtain for each infant a fine picture of the acquisition process of malaria humoral immunity30.
At last, this study demonstrates the huge importance to give to key factors conditioning the antibody response 
in early life (age, malaria antibody levels at birth, previous and present malaria infections as well as exposure to 
Anopheles bites). Such factors have to be considered simultaneously in follow-ups of cohorts aimed at elucidating 
the specific humoral response mainly in the context of vaccine trials.
Methods
Study design and sample collection. The study took place in Southern Benin where P. falciparum is the 
commonest species (95%)31 and where the entomological inoculation rate is 15.48 infected anopheles/person per 
year12. Between June 2007 and July 2008, 656 newborns were enrolled and 567 infants remained for this study 
(10 stillbirths, 16 infants deceased before Day 28, 10 infants lost of sight, 25 twin pairs and one set of triplets)12.
Briefly, at delivery, (i) a questionnaire collecting information on maternal age, parity, use of Intermittent 
Preventive Treatment during pregnancy (IPTp) and bed net possession was administered and (ii) placental blood 
smears were performed and maternal peripheral as well as cord bloods were collected into Vacutainer® EDTA 
(Ethylene diaminetetraacetic acid) tubes.
Every child was visited weekly. In case of fever (axillary temperature ≥ 37.5 °C) and/or a reported 
48-hours-fever episode, a questionnaire and both a rapid diagnostic test (RDT) and a thick blood smear 
(TBS) were performed. Symptomatic malaria infection (fever and positive TBS and/or RDT) was treated with 
artemether and lumefantrine combination therapy as recommended by the National Malaria Control Program. 
Every month, a systematic TBS to detect asymptomatic malaria infection and a qualitative dietary question-
naire32 were performed. Every 3 months (at 3, 6, 9, 12, 15, 18 months of age), infant blood samples were collected 
(in EDTA). Plasmas were conserved at − 80 °C.
Antibody measurements. Antibody measurement by Enzyme-Linked ImmunoSorbent Assay (ELISA). 
ELISA was performed as described previously17 and recalled in the Supplementary material33–38. The Afro 
Variables
AMA1 MSP1 MSP2-3D7 MSP2-FC27 MSP3 GLURP-R0 GLURP-R2
IgG1 IgG3 IgG1 IgG3 IgG1 IgG3 IgG1 IgG3 IgG1 IgG3 IgG1 IgG3 IgG1 IgG3
Constant 3.819 − 1.180 − 1.487 − 4.182 3.784 − 0.961 − 2.805 − 0.322 − 2.350 − 2.834 − 2.171 3.603 − 1.685 − 2.410
Age − 1.018a − 0.581 − 0.325 − 0.181 0.090 − 0.781 0.068 − 0.862 − 0.078* − 0.419 0.050 − 0.224 − 0.189 − 0.552
Age squared 0.037 0.023 0.015 0.008 NS 0.031 NS 0.033 0.005** 0.017 NS 0.009 0.010 0.022
Antibody levels in cord 
blood 0.131 0.097** 0.132 0.060* 0.148 0.209 0.072 0.114** 0.085** NS 0.073** 0.126* NS NS
Antibody levels at 3 months 0.063** 0.135 0.113 0.206 0.129 0.173 0.147 0.140 0.183 0.206 0.147 0.196 0.164 0.169
Infection at 3–6 months 
of age NS NS NS − 0.345** 0.244* NS NS NS NS NS NS − 0.406 NS NS
Infection from 6 months 
of age:
in the 3-month period 
preceding antibody 
measurement
1.335 1.445 2.210 2.222 1.716 1.826 1.696 1.778 0.633 0.945 0.588 0.834 1.436 1.362
in the 3-to-6-month 
period preceding antibody 
measurement
1.443 1.114 1.909 1.277 1.519 1.343 1,494 1.439 0,380 0.51 0.221* 0.240** 0.697 0.499
Environmental variable 0.032 0.024** 0,027* 0,040** 0.039 0.029 NS 0,038** NS NS 0,039 0,019* NS 0,024*
Table 1.  Multivariate analysis: final model indicating factors associated with the acquisition of malaria 
specific cytophilic IgG in infants from 6 to 18 months of age. a: The numbers of the entire Table 1 are 
coefficient of mixed linear regression: a positive (negative) coefficient indicates a positive (negative) effect of the 
variable on antibody levels from 6 until 18 months of life. All associations are significant at a P value of ≤ 0.001 
unless otherwise indicated: NS non-significant, *P < 0.05, **P ≤ 0.01,  with quarterly febrile infection cases,  
 with quarterly non febrile infection cases. Malaria infections in the previous 3-month period are defined as 
the presence of at least one malaria attack between two successive antibody measurements and could be feverish 
or not. The infections in the previous 3-to-6-month period allowed the creation a variable for testing the effect 
of 2 consecutive infections (separated by at least 3 months) on malaria specific antibody responses. Age is in 
months; Infections are coded as: at least one infection = 1, no infection = 0; antibody levels are represented by 
quantitative residual values; the environmental variable is a quantitative index related to the malaria exposure of 
the infant in the area (described elsewhere18).
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Immuno Assay protocols - standard methods developed for evaluating malaria vaccines sponsored by the African 
Malaria Network Trust (AMANET [www.amanet-trust.org]) - were performed to assess malaria antibody con-
centrations by ELISA39,40.
Standard curves were established using human IgG, IgG1 and IgG3 purified proteins (The Binding Site, 
France) to determine the concentration of specific antibodies. Each point was tested in duplicate.
Data Management for ELISA data. The ADAMSEL FLP b039 software (http://www.malariaresearch.eu/content/
software) was used to analyze automatically the ELISA optical density (OD) leading to antibody concentrations. 
Discordant duplicates (with a variation coefficient > 15%) were technically repeated.
OD that were below detection threshold or over saturation were referred as “Low” and “High” concentrations 
(μ g/mL) respectively. These thresholds depend on standard concentrations, normalization procedures and are 
therefore specific to each ELISA plate. These censored values were imputed using a (log) linear regression model 
taking into account confounding variables. The model was fitted using a stochastic expectation maximization 
algorithm41 already applied to ELISA analyses42, and estimated values were attributed to the “Low” and “High” 
censored values. The quality of imputation, assessed by the R2 between imputed and measured values (both in 
log-scale), was very good for both low (R2 = 0.9082 for the 5156 concerned measurements) and high (R2 = 0.9498 
for the 192 concerned measures). The residuals were classically standardized to obtain a Normal distribution. The 
R2 between the imputed values and adjusted residuals (both in log-scale) was 0.9906.
Outcome variable: adjusted antibody level. The outcome variable was time-dependent (at 6, 9, 12, 
15 and 18 months). Antibody levels were firstly adjusted on the nuisance variables using a linear regression for: 
health center, prematurity, parity, use of IPTp, bed net possession and maternal age in order to focus on the effects 
of variables of interest (detailed in “Independent variables” section). The residuals of these adjustments - referred 
as “adjusted antibody level” - were then used as outcome variable.
Independent variables. Maternal, cord and 3-month infant blood samples. Birth and 3-month infant sam-
ples are strongly represented by maternal antibodies that could interfere with the evaluation of acquired IgG of 
neonates43. Antibody measures in these samples were thus used as quantitative variables in the analyses.
Infections. Placental malaria infection was defined by the presence of P. falciparum in thick placental smears.
The number of malaria attacks between two successive antibody measurements was used either as a quantita-
tive or a qualitative variable. Malaria infections could be feverish or not.
The effect of an infection on the antibody levels was tested by two ways: a prospective effect and a boosting 
effect of a second infection. To evaluate the prospective effect, infections occurring in the 3-month period before 
the antibody measurements were considered to be associated with antibody levels. To evaluate the boosting of 
the antibody response in children being infected in the 3-month period before the antibody measurement, we 
considered whether they were also infected in the 3-to-6 month period (2 consecutive infections: one occurring 
in the 3-to-6 month period and one in the 3-month period before the antibody measurements).
Infant’s feeding. Individual 24-Hour Dietary Recall questionnaires - based on child feeding practices32 - were 
administered monthly from birth. A time-dependent quantitative variable accounting for the past 3-month feed-
ing practices was created12.
Figure 4. Level of IgG1 specific to MSP3 predicted by the mixed linear model IgG1 specific to MSP3 levels 
are the residuals of adjustments (cf Materials and Methods -Outcome variable). The effect of an infection at 
each 3-month period is estimated in presence or not of an interaction between age and infection. The best fitted 
model includes an interaction between age and infection: the difference between the 2 curves increases with age 
illustrating that more an infant is old and stronger is his response to a first malaria infection.
www.nature.com/scientificreports/
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Sickle-cell trait. Genomic DNA was extracted from buffy coat using QIAamp DNA blood midi kit (Qiagen, 
France). The amplified beta globin DNA was then cleaved by the DdeI enzyme into 3 fragments when normal and 
into 2 fragments when mutated44.
Environmental factors. The environmental risk of exposure to malaria was modeled for each child based on 
climatic, entomological, and characteristics of the children immediate surroundings18. Using this model an indi-
vidual time-dependent risk of exposure was attributed to each child, depending on his birthday and on his house’s 
location in the area.
Statistical analyses. During the study period, antibodies levels were determined quarterly, and the child’s 
measurements cannot be considered independent. Therefore, child’s antibody levels presented a two-level hier-
archy: antibody measurements (level 1) were clustered within children (level 2)45. A linear mixed model with 
assumed independent random-coefficients was used for both univariate and multivariate analyses. Hierarchical 
mixed models are well suited to this type of data, allowing analyzing the time dependent evolution of antibod-
ies, and were used in this study45 for both univariate and multivariate analyses. Variance components and fixed 
effects parameters were estimated using the restricted and the not restricted maximum likelihood methods, 
respectively45.
The effect of age on the acquisition of natural antibodies was tested using polynomial models. The best fitted 
model (Bayesian Information Criterion) was used for further analyses.
Multivariate analysis was performed including the variables with P ≤ 0.20 in the univariate step. Placental 
malaria was systematically included in multivariate analyses. An interaction between age and infection was tested 
in the model. All statistical analyses were performed using Stata, version 11.0 (StatCorp LP, TX, USA). Statistical 
significance was set at P < 0.05.
Ethics. The study protocol was approved by the University of Abomey-Calavi’s institutional review board and 
the IRD’s Consultative Ethics Committee. All women in this study signed an informed consent before enrollment 
(which also included their children) with the possibility to withdraw at any time. All the methods were carried 
out in accordance with the approved guidelines.
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